伦瓦提尼
医学
彭布罗利珠单抗
内科学
队列
肿瘤科
甲状腺癌
临床终点
无进展生存期
不利影响
癌症
临床试验
化疗
免疫疗法
作者
Jena D. French,Bryan R. Haugen,Francis P. Worden,Daniel W. Bowles,Andrew G. Gianoukakis,Bhavana Konda,Ramona Dadu,Eric J. Sherman,Shaylene McCue,Nathan R. Foster,Yuri E. Nikiforov,Ticiana D.J. Farias,Paul J. Norman,Lori J. Wirth
标识
DOI：10.1158/1078-0432.ccr-23-3417
摘要
Lenvatinib, a potent multi-kinase inhibitor, improves progression-free survival (PFS) in patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC); however, most patients experience disease progression, warranting further therapy. We evaluated the efficacy and safety of combination lenvatinib plus pembrolizumab (LP) in these patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI
寻道图强
随机子
shinysparrow
竹筏过海
吃不饱星球球长
穆紫
misha991
沸腾的大海
加菲丰丰
Puan
oceanao
iWatchTheMoon
清脆松
积极慕梅
jyy
科目三
丘比特
贪玩访琴
充电宝
Migue
皖公网安备34019202002308
